Biotechnology

Hundreds of lupus advocates descended on Washington, demanding policy reform and research funding, and their persistent efforts are already yielding major results.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

Forge Biologics is one of few CDMOs globally to earn top sustainability honors, signaling a major shift toward greener practices in the biopharma industry.

A new state-of-the-art facility in Chicago aims to secure life-saving medicines, as GEODIS enters a heated race for pharmaceutical logistics dominance.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

A new imaging tool eliminates background noise, offering a revolutionary, high-definition view into the cellular processes that drive life and disease.

A new powerhouse residency program backed by Silicon Valley elite launches near Stanford to turn academic science into fundable healthcare companies.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

Remix Therapeutics' first-in-class drug REM-422 targets a rare cancer at its genetic source, with pivotal data set for a major oncology conference.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

Adocia extends its cash runway to 2027 with a new loan, but the deal could make its key investor the largest shareholder, creating a dilution dilemma.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.

Dizal to unveil late-breaking ZEGFROVY data for NSCLC, plus new findings for drugs tackling resistance and boosting immunotherapy at ASCO 2026.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

Biotech firm Northwest Biotherapeutics is opening a private clinic to speed up cancer therapy access, a strategic move to control its supply chain.